Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Evelo Biosciences Inc.
said Tuesday it’s reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The study’s primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index score between EDP2939 and placebo after 16 weeks of daily treatment, was not achieved,” the company said in a statement. It’s still gathering and analyzing the data.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP BiosciencesTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Les mer »
Cruising is no longer a crime in CaliforniaCiara Encinas joined the ABC 10News team in December 2021 as a multimedia journalist.
Les mer »
Best Buy plans to phase out sales of physical movies in the coming monthsBest Buy said it will stop selling DVDs and Blue-rays by early next year. This doesn’t include video games. Best Buy follows Netflix which in September...
Les mer »
City of Indianapolis breaks ground on next phase of Pogue's Run TrailJacqueline is a graduate of Indiana University where she studied Journalism with a concentration in digital journalism.
Les mer »
Israel-Hamas war enters diplomatic phase as civilians flee GazaThis is additional taxonomy that helps us with analytics
Les mer »
Marvel Secretly Introduced A Way To Bring Thanos Back To The MCU After Phase 6Though the Infinity Saga and Thanos' reign are over, there is a way for him to return beyond Phase 6 thanks to a recent MCU twist reveal.
Les mer »